Cyanotic heart defect medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 4: | Line 4: | ||
{{CMG}} | {{CMG}} | ||
'''Associate Editor(s)-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu], Atif Mohammad, M.D. | '''Associate Editor(s)-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu], Atif Mohammad, M.D.; {{KD}} | ||
==Overview== | ==Overview== | ||
Line 15: | Line 15: | ||
*Help the heart pump harder | *Help the heart pump harder | ||
*Treat abnormal heartbeats or rhythms | *Treat abnormal heartbeats or rhythms | ||
* Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established. | * Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established. | ||
Latest revision as of 22:03, 18 October 2012
Cyanotic heart defect Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cyanotic heart defect medical therapy On the Web |
American Roentgen Ray Society Images of Cyanotic heart defect medical therapy |
Risk calculators and risk factors for Cyanotic heart defect medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor(s)-In-Chief: Keri Shafer, M.D. [2], Atif Mohammad, M.D.; Kalsang Dolma, M.B.B.S.[3]
Overview
Medical Therapy
Infants that remain in the hospital may receive medicines to:
- Get rid of extra fluids
- Help the heart pump harder
- Treat abnormal heartbeats or rhythms
- Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established.